- Home
- EDIT vs MHLD Comparison
EDIT vs MHLD Comparison
Compare EDIT & MHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- MHLD
- Stock Information
- Founded
- EDIT 2013
- MHLD 2007
- Country
- EDIT United States
- MHLD Bermuda
- Employees
- EDIT N/A
- MHLD N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- MHLD Property-Casualty Insurers
- Sector
- EDIT Health Care
- MHLD Finance
- Exchange
- EDIT Nasdaq
- MHLD Nasdaq
- Market Cap
- EDIT 108.1M
- MHLD 96.4M
- IPO Year
- EDIT 2016
- MHLD 2008
- Fundamental
- Price
- EDIT $1.25
- MHLD $0.61
- Analyst Decision
- EDIT Buy
- MHLD
- Analyst Count
- EDIT 14
- MHLD 0
- Target Price
- EDIT $8.08
- MHLD N/A
- AVG Volume (30 Days)
- EDIT 2.5M
- MHLD 166.1K
- Earning Date
- EDIT 03-05-2025
- MHLD 03-10-2025
- Dividend Yield
- EDIT N/A
- MHLD N/A
- EPS Growth
- EDIT N/A
- MHLD N/A
- EPS
- EDIT N/A
- MHLD N/A
- Revenue
- EDIT $32,314,000.00
- MHLD $56,436,000.00
- Revenue This Year
- EDIT N/A
- MHLD N/A
- Revenue Next Year
- EDIT N/A
- MHLD N/A
- P/E Ratio
- EDIT N/A
- MHLD N/A
- Revenue Growth
- EDIT N/A
- MHLD N/A
- 52 Week Low
- EDIT $1.12
- MHLD $0.61
- 52 Week High
- EDIT $7.41
- MHLD $2.27
- Technical
- Relative Strength Index (RSI)
- EDIT 41.70
- MHLD 35.32
- Support Level
- EDIT $1.24
- MHLD $0.67
- Resistance Level
- EDIT $1.32
- MHLD $0.75
- Average True Range (ATR)
- EDIT 0.11
- MHLD 0.08
- MACD
- EDIT -0.03
- MHLD -0.01
- Stochastic Oscillator
- EDIT 2.94
- MHLD 0.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.